Sagimet Biosciences Inc Series A (SGMT)

Mar 12, 2025, 7:30 AM EDT - 22 days ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Mar 11, 2025, 8:00 AM EDT - 23 days ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Mar 7, 2025, 4:27 PM EST - 27 days ago

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Nov 14, 2024, 3:56 PM EST - 5 months ago

Sagimet: More Than Just A MASH Drug Development Biotech

Nov 12, 2024, 6:30 AM EST - 5 months ago

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Oct 18, 2024, 3:10 PM EDT - 5 months ago

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Oct 11, 2024, 7:00 AM EDT - 6 months ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Oct 1, 2024, 7:00 AM EDT - 6 months ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Oct 1, 2024, 12:05 AM EDT - 6 months ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 12, 2024, 7:30 AM EDT - 7 months ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Aug 1, 2024, 8:00 AM EDT - 8 months ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Jul 31, 2024, 12:24 PM EDT - 8 months ago

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Jun 10, 2024, 8:00 AM EDT - 10 months ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Jun 6, 2024, 5:00 AM EDT - 10 months ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

May 16, 2024, 8:00 AM EDT - 11 months ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 15, 2024, 8:00 AM EDT - 11 months ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 7, 2024, 8:00 AM EDT - 11 months ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

May 6, 2024, 8:00 AM EDT - 11 months ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Apr 26, 2024, 12:23 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mar 25, 2024, 6:15 AM EDT - 1 year ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Feb 29, 2024, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Jan 25, 2024, 8:58 PM EST - 1 year ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Jan 24, 2024, 1:55 PM EST - 1 year ago

Sagimet: Additional Upside Possible After Latest NASH Data Release

Jan 23, 2024, 5:45 PM EST - 1 year ago

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Jan 22, 2024, 11:10 PM EST - 1 year ago

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 7:00 AM EST - 1 year ago

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Dec 4, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Nov 28, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

Nov 22, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 13, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 10, 2023, 8:30 AM EST - 1 year ago

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Oct 24, 2023, 11:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

Oct 18, 2023, 4:05 PM EDT - 1 year ago

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Sep 27, 2023, 4:05 PM EDT - 1 year ago

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Sep 27, 2023, 2:48 PM EDT - 1 year ago

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

Aug 21, 2023, 4:02 PM EDT - 1 year ago

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Aug 15, 2023, 4:04 PM EDT - 1 year ago

Sagimet Biosciences Announces Closing of Underwriters' Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering

Jul 20, 2023, 4:05 PM EDT - 1 year ago

Sagimet Biosciences Announces Leadership Changes

Jul 15, 2023, 3:28 AM EDT - 1 year ago

U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs

APGE ODD OPHV SRFM TURB

Jul 13, 2023, 9:10 PM EDT - 1 year ago

Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering

Jul 11, 2023, 5:41 PM EDT - 1 year ago

IPO Update: Sagimet Biosciences Pushes Forward On IPO Plan

Jul 10, 2023, 7:05 AM EDT - 1 year ago

Sagimet Biosciences sets IPO terms, to raise up to about $80 million